FDA approves Capsida’s CAP-003 gene therapy for Parkinson’s
CAP-003 leverages an engineered capsid capable of crossing the blood-brain barrier.
Cytiva Pipe dream to pipeline WP 3
SpliceBio secures $135m for gene therapy development
FDA grants RMAT designation to AbelZeta’s CAR-T therapy
AGC Biologics and Quell to progress Treg cell therapy development
FDA grants RMAT status to Opus Genetics’ OPGx-LCA5 gene therapy
Atsena closes $150m in Series C round to progress gene therapy
Alltrna plans to tackle rare diseases using tRNA-based therapies
Struggling bluebird bio to go private for less than $30m
